Overview: Phosphatidylserine IgM TestIntroduction: The Phosphatidylserine IgM Test detects PS IgM to diagnose antiphospholipid syndrome, causing thrombosis or pregnancy loss. Aligned with 2023 ACR guidelines, it uses immunoassays for high specificity, supporting autoimmune screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected antiphospholipid syndrome.
Other Names: PS IgM Assay, Antiphospholipid IgM Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Antiphospholipid antibody testing began in the 1980s with lupus anticoagulant research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects PS IgM to diagnose antiphospholipid syndrome, guides treatment, and evaluates patients with thrombosis or pregnancy loss.
Test Parameters: 1. Phosphatidylserine IgM Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of thrombosis, pregnancy loss, or autoimmune symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document thrombosis, pregnancy loss, or history of autoimmune diseases. Include current medications, especially anticoagulants.
Consent: Written consent required, detailing the tests purpose, antiphospholipid syndrome implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect PS IgM antibodies. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for antiphospholipid syndrome diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other autoantibodies may reduce specificity.
Clinical Significance: Positive PS IgM confirms antiphospholipid syndrome, guiding anticoagulant therapy. Negative results may require additional antibody testing.
Specialist Consultation: Consult a rheumatologist or hematologist for result interpretation and treatment planning.
Additional Supporting Tests: Lupus anticoagulant, anticardiolipin antibodies, or beta-2 glycoprotein I antibodies to confirm antiphospholipid syndrome diagnosis.
Test Limitations: Non-specific for certain autoimmune conditions; clinical correlation is needed. Sample quality affects sensitivity.
References: ACR Antiphospholipid Syndrome Guidelines, 2023; Arthritis & Rheumatology, Miyakis S, 2022.
